MedWatch

Swedish company fails in study of diabetes vaccine

In a study with children at risk of developing type 1 diabetes, an experimental vaccine from Sweden's Diamyd Medical has failed to show a significant difference from placebo. The result cut off more than 20 percent of the company’s share price in just two days.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

MedWatch-indeks: Endnu en tung uge for biotekaktierne

Nedturen ser ud til at fortsætte for de danske biotekaktier, som alle oplevede kursfald i uge 47. Novo Nordisk ender for en efterhånden sjælden gangs skyld på toppen i MedWatch-indekset, efter at have givet markedet tiltro til fremtiden på sin kapitalmarkedsdag.

Latest Top picks in English

Related articles